Editing Maprotiline (section)

==Medical uses==
Maprotiline is used in the treatment of depression, such as depression associated with agitation or anxiety and has similar efficacy to the antidepressant drug [[moclobemide]].<ref name="pmid8557884">{{cite journal | vauthors = Delini-Stula A, Mikkelsen H, Angst J | title = Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies | journal = Journal of Affective Disorders | volume = 35 | issue = 1–2 | pages = 21–30 | date = October 1995 | pmid = 8557884 | doi = 10.1016/0165-0327(95)00034-K }}</ref> This finding has also been validated by a group of [[general practitioner]]s who compared the respective efficacy and tolerability of maprotiline and [[moclobemide]].<ref name="pmid7954482">{{cite journal | vauthors = Gachoud JP, Dick P, Köhler M | title = Comparison of the efficacy and tolerability of moclobemide and maprotiline in depressed patients treated by general practitioners | journal = Clinical Neuropharmacology | volume = 17 | issue = Suppl 1| pages = S29–37 | date = 1994 | pmid = 7954482 | doi = 10.1097/00002826-199417001-00005 | s2cid = 260560762 | url = }}</ref>
* Treatment of [[clinical depression|depression]] of all forms and severities ([[Endogenous depression|endogenous]], [[Psychotic depression|psychotic]], [[Involutional melancholia|involutional]], and [[Neurotic depression|neurotic]]), especially depression associated with agitation or anxiety
* [[Panic disorder]]
* [[Neuropathic pain]], including painful [[polyneuropathy]] in diabetics and non-diabetics alike.<ref name="pmid9430812">{{cite journal | vauthors = Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindström T, Thorell LH | title = A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics | journal = The Clinical Journal of Pain | volume = 13 | issue = 4 | pages = 313–23 | date = December 1997 | pmid = 9430812 | doi = 10.1097/00002508-199712000-00009 }}</ref>
* Treatment of the depressive phase of [[bipolar disorder|bipolar affective disorder]]
* For the symptomatic relief of [[anxiety]], [[stress (medicine)|tension]] or [[insomnia]]

The use of maprotiline in the treatment of [[enuresis]] in [[pediatric]] patients has so far not been systematically explored and its use is not recommended.<ref name = DrugDex /> Safety and effectiveness in the pediatric population in general have not been established. Anyone considering the use of maprotiline in a child or adolescent must balance the potential risks with the clinical need.

A very small body of research has also explored the potential of maprotiline in treating [[diabetic nephropathy|diabetic kidney disease]]<ref>Zhou, Z. and Liu, S., 2022. Maprotiline Ameliorates High Glucose-Induced Dysfunction in Renal Glomerular Endothelial Cells. Experimental and Clinical Endocrinology & Diabetes, 130(09), pp.596-603.</ref> and it has been measured against [[amitriptyline]] in this regard.<ref name="pmid24373831">{{cite journal | vauthors = Singh R, Kishore L, Kaur N | title = Diabetic peripheral neuropathy: current perspective and future directions | journal = Pharmacological Research | volume = 80 | issue = | pages = 21–35 | date = February 2014 | pmid = 24373831 | doi = 10.1016/j.phrs.2013.12.005 | s2cid = 6097534 }}</ref>

Maprotiline and [[fluoxetine]] have also been found, among certain lines of research, to have quite potent anti-profilerative effects against certain forms of cancer of the [[Burkitt lymphoma]] type.<ref name="pmid20141432">{{cite journal | vauthors = Cloonan SM, Drozgowska A, Fayne D, Williams DC | title = The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters | journal = Leukemia & Lymphoma | volume = 51 | issue = 3 | pages = 523–39 | date = March 2010 | pmid = 20141432 | doi = 10.3109/10428190903552112 | s2cid = 33104465 | url = }}</ref><ref name="pmid20503272">{{cite journal | vauthors = Cloonan SM, Williams DC | title = The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma | journal = International Journal of Cancer | volume = 128 | issue = 7 | pages = 1712–23 | date = April 2011 | pmid = 20503272 | doi = 10.1002/ijc.25477 | s2cid = 24955263 | url = }}</ref> One study also bore ought a certain level of evidence regarding maprotiline’s ability to suppress both [[cholesterol]] biosynthesis and [[hepatocellular carcinoma]] liver-cancer progression.

Maprotiline was also measured against [[imipramine]], [[fluoxetine]] and [[ketamine]] in an experiment-model involving two different kinds of [[chicken]] differently-conditioned against [[Stress (biology)|stress]], including (black) [[Australorp]]s in the proposed treatment of treatment-resistant depression in humans.<ref name="pmid24157688">{{cite journal | vauthors = Sufka KJ, White SW | title = Identification of a treatment-resistant, ketamine-sensitive genetic line in the chick anxiety-depression model | journal = Pharmacology, Biochemistry, and Behavior | volume = 113 | issue = | pages = 63–7 | date = November 2013 | pmid = 24157688 | doi = 10.1016/j.pbb.2013.10.013 | s2cid = 23648185 | url = }}</ref>

In general, lower dosages are recommended for patients over 60 years of age. Dosages of 50&nbsp;mg to 75&nbsp;mg daily are usually satisfactory as maintenance therapy for elderly patients who do not tolerate higher amounts.<ref>{{cite web |url=https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682158.html |title=Maprotiline: MedlinePlus Drug Information |website=www.nlm.nih.gov |access-date=29 September 2013}}</ref><ref>{{cite web |url=https://www.drugs.com/pro/maprotiline.html |title=Maprotiline - FDA prescribing information, side effects and uses |website=www.drugs.com |access-date=29 September 2013 |archive-date=30 December 2019 |archive-url=https://web.archive.org/web/20191230233959/https://www.drugs.com/pro/maprotiline.html |url-status=dead }}</ref> In any case, 225 m.g./d. is the absolute-maximum highest recommended dose for this drug, as any more can predispose more significantly to seizures. 150 m.g. is the average optimal daily dose for otherwise-healthy patients who can tolerate a full dose.

===Available forms===
* Coated tablets: 10&nbsp;mg, 25&nbsp;mg, 50&nbsp;mg, and 75&nbsp;mg
* Injectable concentrate, 25&nbsp;mg